We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.57B
AUM Growth
-$21.5M
Cap. Flow
+$32.3M
Cap. Flow %
1.25%
Top 10 Hldgs %
39.02%
Holding
197
New
37
Increased
49
Reduced
41
Closed
10

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$39M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.2M
3
ESPR
Esperion Therapeutics
ESPR
+$13.9M
4
ABBV icon
AbbVie
ABBV
+$11.5M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$36.3M
2
AMGN icon
Amgen
AMGN
+$29.7M
3
BIIB icon
Biogen
BIIB
+$20.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$19.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.47%
2 Real Estate 2.71%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MPT
51
Medical Properties Trust
MPT
$2.81B
$11.2M 0.43%
858,586
– –
WELL.PRI
52
DELISTED
Welltower Inc.
WELL.PRI
$11.1M 0.43%
200,000
– –
XLRN
53
DELISTED
Acceleron Pharma
XLRN
$10.7M 0.42%
273,098
-10,285
-4% -$437K
ACHC icon
54
Acadia Healthcare
ACHC
$2.62B
$10.7M 0.42%
272,400
– –
SYK icon
55
Stryker
SYK
$133B
$10.3M 0.4%
64,258
+32,758
+104% +$5.28M
DHC
56
Diversified Healthcare Trust
DHC
$2.17B
$10.1M 0.39%
646,554
– –
ADAP
57
DELISTED
Adaptimmune Therapeutics
ADAP
$9.61M 0.37%
855,468
-79,900
-9% -$699K
LKFT
58
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$9.54M 0.37%
95,635
+42,435
+80% +$4.57M
CI icon
59
Cigna
CI
$76.1B
$9.49M 0.37%
56,563
-43,439
-43% -$8.44M
EW icon
60
Edwards Lifesciences
EW
$50B
$9.25M 0.36%
198,825
+3,525
+2% +$153K
MDCO
61
DELISTED
Medicines Co
MDCO
$9.17M 0.36%
+278,391
New +$8.7M
ZBH icon
62
Zimmer Biomet
ZBH
$18.4B
$8.95M 0.35%
84,542
+1,833
+2% +$213K
CLLS
63
Cellectis
CLLS
$287M
$8.93M 0.35%
283,250
-27,000
-9% -$853K
HCA icon
64
HCA Healthcare
HCA
$85.7B
$8.91M 0.35%
91,881
+28,449
+45% +$2.76M
MRUS
65
DELISTED
Merus
MRUS
$8.88M 0.35%
479,150
– –
DPLO
66
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$8.85M 0.34%
439,001
-201,491
-31% -$4.7M
AVXS
67
DELISTED
AveXis, Inc. Common Stock
AVXS
$8.69M 0.34%
70,347
– –
EPZM
68
DELISTED
Epizyme, Inc
EPZM
$8.62M 0.34%
485,325
+29,325
+6% +$495K
EXEL icon
69
Exelixis
EXEL
$14.1B
$8.61M 0.33%
388,822
– –
ONC
70
BeOne Medicines Ltd
ONC
$33.4B
$8.31M 0.32%
49,496
+23,326
+89% +$3.16M
AET
71
DELISTED
Aetna Inc
AET
$8.04M 0.31%
47,566
– –
COR icon
72
Cencora
COR
$60.7B
$7.99M 0.31%
92,707
-74,600
-45% -$7.17M
LTC
73
LTC Properties
LTC
$2.06B
$7.97M 0.31%
209,673
– –
RARE icon
74
Ultragenyx Pharmaceutical
RARE
$2.56B
$7.58M 0.29%
148,558
– –
CTMX icon
75
CytomX Therapeutics
CTMX
$714M
$7.54M 0.29%
265,045
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Tekla Capital Management held 197 positions worth $2.57B, down 0.83% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q1 2018 filing shows 37 new, 49 increased, 41 reduced and 10 closed positions. Its largest new stake was Esperion Therapeutics: 189,287 shares worth $13.7M. The largest sale was Gilead Sciences, an estimated $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q1 2018 buy was Esperion Therapeutics: 189,287 shares worth $13.7M.
  • Tekla Capital Management added most to Pfizer in Q1 2018, an estimated $39M increase.
  • Tekla Capital Management's biggest Q1 2018 reduction was Gilead Sciences, cutting an estimated $36.3M.
  • Tekla Capital Management fully exited NuVasive, Inc. in Q1 2018, selling an estimated $6.87M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.57B portfolio in Q1 2018.
  • Tekla Capital Management opened 37 new positions and closed 10 in Q1 2018.
  • Tekla Capital Management's portfolio value fell 0.83% quarter-over-quarter to $2.57B.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.